دورية أكاديمية
A prospective trial of CT-guided percutaneous microwave ablation for lung tumors.
| العنوان: | A prospective trial of CT-guided percutaneous microwave ablation for lung tumors. |
|---|---|
| المؤلفون: | Reisenauer JS; Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA., Eiken PW; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Callstrom MR; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Johnson GB; Department of Radiology, Mayo Clinic, Rochester, MN, USA.; Department of Immunology, Mayo Clinic, Rochester, MN, USA., Pierson K; Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA., Lechtenberg B; Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA., Blackmon SH; Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA. |
| المصدر: | Journal of thoracic disease [J Thorac Dis] 2022 Apr; Vol. 14 (4), pp. 939-951. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: AME Publishing Company Country of Publication: China NLM ID: 101533916 Publication Model: Print Cited Medium: Print ISSN: 2072-1439 (Print) Linking ISSN: 20721439 NLM ISO Abbreviation: J Thorac Dis Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: Hong Kong : AME Publishing Company Original Publication: Hong Kong : Pioneer Bioscience Pub. Co. |
| مستخلص: | Background: Percutaneous ablation is an alternative treatment for lung cancer in non-operable patients. This is a prospective clinical trial for percutaneous microwave ablation (pMWA) of biopsy-proven lung cancer to demonstrate safety and efficacy. Methods: A prospective trial from 6-1-2016 to 1-1-2019 enrolled patients with biopsy-proven primary or metastatic lung cancer <3 cm in size and 1 cm away from the pleura for pMWA with the Emprint Ablation System with Thermosphere Technology for Phase I analysis, (Clinicaltrials.gov; #NCT0267302). Patients were followed for 1 year with PET/CT and PET/MR to determine patterns of recurrence and efficacy of ablation. Results: After 12 patients consented for biopsy, 6 patients underwent treatment of 7 lesions, 3/6 women, median age of 67 (IQR, 65-70) years, body mass index (BMI): 27.8 (IQR, 21.4-32.1) kg/m 2 , lesion distance to pleura 24.4 (IQR, 13-38) mm, lesion size of 10.7 (IQR, 6-14) mm, and ablation duration time 5.9 (IQR, 3-10) minutes. pMWA were completed at 75 W. Twelve adverse events were reported (1 Grade 3, 3 Grade 2, and 8 Grade 1 events) with Grade 4 or 5 events. Mean % change after ablation in forced expiratory volume in one second (FEV1) was -2% and diffusion capacity for carbon monoxide (DLCO) was -1%. After 2-3 months, the lesions would decrease in size, rim thickness, fluorodeoxyglucose (FDG) activity, and T2 signal. FDG activity after 6 months was below blood pool in all cases. The ablation zones stabilized by 6-12 months. One patient expired during the study from pneumonia unrelated to ablation without local recurrence. Of the seven ablations during the 1 year follow-up, there was local tumor recurrence at 271 days following ablation at the apex of the ablation zone, subsequently successfully treated with percutaneous cryoablation (Cryo). Conclusions: pMWA appears to be a safe and effective mechanism for treatment of primary and secondary tumors of the lung, with possible preservation of pulmonary function. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-21-1636/coif) and report that financial support in the amount of $200,000 was provided by Covidien for conducting this study. The authors have no other conflicts of interest to declare. (2022 Journal of Thoracic Disease. All rights reserved.) |
| References: | Ann Thorac Surg. 2014 Jul;98(1):243-8. (PMID: 24793688) Cardiovasc Intervent Radiol. 2018 Oct;41(10):1530-1544. (PMID: 29845348) Cancer Sci. 2019 Nov;110(11):3553-3564. (PMID: 31464032) J Thorac Cardiovasc Surg. 2013 Mar;145(3):692-9. (PMID: 23174176) J Thorac Oncol. 2015 Oct;10(10):1468-74. (PMID: 26230972) Transl Lung Cancer Res. 2014 Aug;3(4):212-24. (PMID: 25806303) Radiology. 2008 Jun;247(3):871-9. (PMID: 18372457) Int J Hyperthermia. 2018 Sep;34(6):883-890. (PMID: 28877612) J Surg Oncol. 2014 Nov;110(6):758-63. (PMID: 24965604) Radiology. 2004 Apr;231(1):143-9. (PMID: 14990816) Int J Hyperthermia. 2018 Jun;34(4):492-500. (PMID: 28774210) Radiographics. 2014 Sep-Oct;34(5):1344-62. (PMID: 25208284) Radiology. 2011 Nov;261(2):643-51. (PMID: 22012906) J Cardiothorac Surg. 2018 Aug 24;13(1):91. (PMID: 30143031) Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1378-1390. (PMID: 27479723) Ann Oncol. 2015 May;26(5):987-991. (PMID: 25688058) J Nucl Med. 2014 May 8;55(Supplement 2):59S-62S. (PMID: 24812246) Int J Surg. 2008;6 Suppl 1:S65-9. (PMID: 19186116) Thorac Cardiovasc Surg. 2009 Dec;57(8):472-5. (PMID: 20013621) Radiology. 2005 Jul;236(1):132-9. (PMID: 15987969) Int J Hyperthermia. 2018 Jun;34(4):486-491. (PMID: 28847194) Thorax. 2001 Jan;56(1):59-61. (PMID: 11120906) J Thorac Oncol. 2020 Jul;15(7):1200-1209. (PMID: 32151777) Cancer. 2015 Oct 1;121(19):3491-8. (PMID: 26096694) Lancet Oncol. 2008 Jul;9(7):621-8. (PMID: 18565793) Eur Radiol. 2021 Apr;31(4):2173-2182. (PMID: 32997180) Med Oncol. 2017 May;34(5):96. (PMID: 28417355) |
| فهرسة مساهمة: | Keywords: Lung cancer; ablation; lung ablation; metastasectomy |
| تواريخ الأحداث: | Date Created: 20220516 Latest Revision: 20220519 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9096293 |
| DOI: | 10.21037/jtd-21-1636 |
| PMID: | 35572874 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2072-1439 |
|---|---|
| DOI: | 10.21037/jtd-21-1636 |